Skip header and navigation

Refine By

10 records – page 1 of 1.

[Antiheparin and heparin activity of blood in various stages of pregnancy]

https://arctichealth.org/en/permalink/ahliterature66670
Source
Pediatr Akus Ginekol. 1970 Jul-Aug;4:33-5
Publication Type
Article

[Dynamics of the heparin and histamine indices in acute respiratory infection in children]

https://arctichealth.org/en/permalink/ahliterature43468
Source
Pediatr Akus Ginekol. 1973;1:14-5
Publication Type
Article
Date
1973

[Heparin activity of blood plasma in patients with eczema, neurodermatitis and psoriasis in the treatment with Krasnodar iodobromine baths].

https://arctichealth.org/en/permalink/ahliterature255909
Source
Vopr Kurortol Fizioter Lech Fiz Kult. 1972;37(1):52-6
Publication Type
Article
Date
1972

[Histamine and heparin metabolism in children with chronic gastritis and ulcer disease]

https://arctichealth.org/en/permalink/ahliterature42728
Source
Pediatr Akus Ginekol. 1975 Mar-Apr;(2):22-4
Publication Type
Article

Interlaboratory variation in heparin monitoring: Lessons from the Quality Management Program of Ontario coagulation surveys.

https://arctichealth.org/en/permalink/ahliterature141872
Source
Thromb Haemost. 2010 Oct;104(4):837-44
Publication Type
Article
Date
Oct-2010
Author
Adam Cuker
Anne Raby
Karen A Moffat
Greg Flynn
Mark A Crowther
Author Affiliation
University of Pennsylvania, Philadelphia, Pennsylvania, USA. adam.cuker@uphs.upenn.edu
Source
Thromb Haemost. 2010 Oct;104(4):837-44
Date
Oct-2010
Language
English
Publication Type
Article
Keywords
Blood Coagulation Tests - methods
Factor Xa - metabolism
Health Care Surveys
Heparin - blood
Humans
International Normalized Ratio
Laboratories, Hospital - statistics & numerical data
Observer Variation
Ontario
Quality Assurance, Health Care
Reproducibility of Results
Sensitivity and specificity
Abstract
Unfractionated heparin (UFH) monitoring is subject to substantial interlaboratory variation. We analysed results of annual coagulation surveys administered by the Quality Management Program - Laboratory Services (Toronto, ON, Canada) from 2003 to 2007 to evaluate variation in UFH monitoring across Ontario. Participating laboratories performed an activated partial thromboplastin time (APTT) utilising their local methodology on lyophilised human plasma spiked with UFH. In the 2006 and 2007 surveys, laboratories licensed to perform anti-Xa assays also reported anti-Xa activity results. The APTT differed significantly between heparin-sensitive and heparin-insensitive methods (p
PubMed ID
20664895 View in PubMed
Less detail

Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators.

https://arctichealth.org/en/permalink/ahliterature212593
Source
Am Heart J. 1996 Mar;131(3):421-33
Publication Type
Article
Date
Mar-1996
Author
R C Becker
C P Cannon
R P Tracy
B. Thompson
E G Bovill
P. Desvigne-Nickens
A M Randall
G. Knatternud
E. Braunwald
Author Affiliation
Thrombosis Research Center, University of Massachusetts Medical School, Worcester 01655-1214, USA.
Source
Am Heart J. 1996 Mar;131(3):421-33
Date
Mar-1996
Language
English
Publication Type
Article
Keywords
Aged
Angina, Unstable - blood - drug therapy
Anticoagulants - therapeutic use
Canada
Female
Heparin - blood - therapeutic use
Humans
Male
Middle Aged
Myocardial Infarction - blood - drug therapy
Myocardial Ischemia - blood - drug therapy
Partial Thromboplastin Time
Plasminogen Activators - therapeutic use
Prospective Studies
Thrombolytic Therapy
Tissue Plasminogen Activator - therapeutic use
United States
Abstract
Although coronary thrombosis is thought to play a pivotal role in the pathogenesis of unstable angina and non-Q wave myocardial infarction and antithrombotic therapy is a mainstay in the early management of these patients, the relation between measures of systemic anticoagulation and clinical events has not been defined clearly. In the Thrombolysis in Myocardial Ischemia III trial, 1473 patients with ischemic chest pain at rest evaluated within 24 hours of symptom onset were randomized to (1) tissue plasminogen activator (TPA) or placebo and (2) an early invasive or an early conservative strategy. All patients received a full complement of anti-ischemic medication, aspirin, and continuous intravenous heparin titrated to an activated partial thromboplastin time (aPTT) of 1.5 to 2.0 times control for 72 to 96 hours. The median aPTT in all study groups exceeded the minimum threshold (45 seconds) by 24 hours and remained within the designated range during the protocol-directed heparin infusion. No differences in median aPTT values for the 72- to 96-hour study period were observed between groups (p=not significant). Median 12-hour heparin concentrations were >0.2 U/ml in all groups; however, values 60 seconds, all heparin levels>0.2 U/ml), and those with aPTTs or heparin levels below these thresholds. Aggressive (high-intensity) anticoagulation with heparin to achieve aPTTs >2.0 times control does not appear to offer additional clinical benefit to lower levels (1.5 to 2.0 times control) among patients with unstable angina and non-Q wave myocardial infarction receiving intravenous heparin and oral aspirin. Therefore, the optimal level of anticoagulation in this common clinical setting is between 45 and 60 seconds when heparin is included in the treatment strategy. Direct plasma heparin measurement does not offer an advantage to routine aPTT monitoring. The occurrence of spontaneous ischemia, myocardial infarction, and death in spite of antischemic therapy and optimal anticoagulation (as it is currently defined) with heparin supports ongoing efforts to develop more effective antithrombotic agents.
PubMed ID
8604620 View in PubMed
Less detail

[State of physiological anticoagulant heparin, antithrombin III and their correction with medicines in patients with acute viral myocarditis]

https://arctichealth.org/en/permalink/ahliterature94527
Source
Lik Sprava. 2008 Oct-Dec;(7-8):31-4
Publication Type
Article
Author
Doroshenko B H
Saliuta M Iu
Nazar P S
Kotko D M
Karpenko O I
Bezuhlova S V
Source
Lik Sprava. 2008 Oct-Dec;(7-8):31-4
Language
Ukrainian
Publication Type
Article
Keywords
Acute Disease
Adolescent
Adult
Antithrombin III - analysis - physiology
Blood Coagulation - physiology
Combined Modality Therapy
Drug Therapy, Combination
Heparin - blood - physiology
Humans
Middle Aged
Myocarditis - blood - therapy - virology
Plasma Exchange
Severity of Illness Index
Virus Diseases - blood - therapy
Young Adult
Abstract
For the first time, positive influence was shown of a complex blood heparin-antitrombin III on the state of the coagulant and fibrinolytic system of blood in patients with acute virus myocarditis that favours the normalization of clinical and laboratory indicators, improvement of the state of patients and reduction of average bed-day indicator (hospital stay) till 25 and 35 days in accordance with severity of clinical course of the disease and can be recommended as a choice of medicine.
PubMed ID
19663013 View in PubMed
Less detail

[The effect of Matsesta baths in the general complex of health resort therapy on the content of heparin and beta-lipoproteins in the blood serum of patients with atherosclerosis]

https://arctichealth.org/en/permalink/ahliterature74809
Source
Vopr Kurortol Fizioter Lech Fiz Kult. 1969 May-Jun;34(3):255-6
Publication Type
Article

10 records – page 1 of 1.